US Patent

US12290596 — Compositions and methods for the treatment of opioid overdose

Method of Use · Assigned to Indivior UK Ltd · Expires 2042-08-04 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects drug products adapted for nasal delivery containing nalmefene hydrochloride for treating opioid overdose.

USPTO Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.

Drugs covered by this patent

nalmefene-hydrochloride (NALMEFENE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4182`	—	nalmefene-hydrochloride

Patent Metadata

Patent number: US12290596
Jurisdiction: US
Classification: Method of Use
Expires: 2042-08-04
Drug substance claim: No
Drug product claim: No
Assignee: Indivior UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.